WELCOME TO The PHARMACEUTICAL REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Aurobindo Pharma | September 29, 2016
The generic drugmaker Aurobindo Pharma U.S.A. Inc. will not longer be pursuing $200,000 in incentives through the city of Durham. The city was alerted to the agreement termination in a letter from the company on September 6. The city council was told today in an email from city manager Tom Bonfield…...
Brand India Pharma | January 03, 2017
Aurobindo Pharma Limited has received US Food &Drug Administration (USFDA) approval to make and market heartburn relief medicine Famotidine tablets of strengths 10 mg and 20 mg and Oxymorphone Hydrochloride Tablets of strengths 5 mg and 10 mg . The estimated market size for Famotidine for the 12 month period ending February 2016 was US$ 31 million whereas for Oxymorphone Hydrochloride Tablets, it is US$ 55.5 million for the same period as per data by IMS....
Aurobindo Pharma USA, Inc. | February 13, 2017
Indian company Aurobindo Pharma has acquired four cell culture-derived biosimilar products from Swiss-based TL Biopharmaceutical. Under the agreement, TL will supply all the developmental data for four molecules and the products will be globally developed, commercialised and marketed by Aurobindo and its affiliates....
Business Today | March 15, 2017
Drug firm Aurobindo Pharma has received final approval from USFDA to manufacture and market Ibandronate Sodium tablets....
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE